Journals
Publish with us
Publishing partnerships
About us
Blog
Chemotherapy Research and Practice
Table of Contents
Special Issues
Chemotherapy Research and Practice
/
2017
/
Article
/
Tab 2
/
Clinical Study
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Table 2
Response to pemetrexed in the 2 cohorts.
Variable
Exon 19 (
)
Exon 21 (
)
CR
ā
ā
PR
11
5
SD
11
5
PD
6
5
Not evaluable
5
7